Atreleuton

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAtreleuton
Drug Alias Name阿曲留通atreleutonumA-85761ABT-761VIA-2291 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukotriene B4 receptor antagonistsArachidonate 5-lipoxygenase inhibitors
TargetsLeukotriene B4 receptorArachidonate 5-lipoxygenase
Therapy Area/IndicationsAtherosclerosisCoronary Artery DiseaseAcute Coronary Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesTallikut Pharmaceuticals IncMadrigal Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsAtherosclerosisCoronary Artery DiseaseAcute Coronary Syndrome +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG